Tesamorelin is the only FDA-approved GHRH analog (2010) for HIV-associated lipodystrophy, demonstrating selective reduction of visceral fat without affecting subcutaneous fat or muscle mass. The N-terminal trans-3-hexenoyl group dramatically increases resistance to dipeptidyl peptidase-IV (DPP-IV) degradation, extending half-life to ~30–60 minutes while preserving full GHRH receptor potency. Daily subcutaneous administration produces physiological GH pulses that preferentially mobilize abdominal fat via enhanced lipolysis and reduced lipogenesis. This research-grade lyophilized powder is synthesized under strict quality controls and provided with full analytical documentation.
Key Scientific
- High-purity Tesamorelin Acetate (≥ 99% by HPLC/MS, acetate salt form)
- Verified 44-amino-acid sequence: (trans-3-hexenoyl)-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH₂
- Lyophilized formulation for maximum long-term stability
- Full Certificate of Analysis (COA) with HPLC, MS, amino acid analysis, and bioactivity assay
- Manufactured in GMP-aligned, ISO-compliant facilities
- Ideal for VAT-specific lipolysis, GH pulsatility, and HIV-lipodystrophy research
Research-Referenced Attributes (Based on scientific literature & clinical trials; not therapeutic claims.)
- FDA-approved (Egrifta®): 2 mg daily → −15.2% visceral adipose tissue at 26 weeks in HIV lipodystrophy
- Selective VAT reduction (−15 to −20%) with no change in subcutaneous fat or muscle
- Increases IGF-1 by 50–100% and improves lipid profile (triglycerides −25%)
- Minimal impact on glucose in non-diabetic subjects (unlike continuous GHRH)
- Restores physiological GH pulsatility — no tachyphylaxis with chronic use
- Valuable in metabolic syndrome, NAFLD, aging-related sarcopenia, and abdominal obesity research
Why Researchers Choose Nationwide Peptides Tesamorelin
- Exact FDA-approved Egrifta® sequence with trans-3-hexenoyl modification
- Highest documented VAT-specific lipolytic activity among GHRH analogs
- Transparent analytical data (HPLC >99%, MS confirmation of full 44-aa + hexenoyl)
- Trusted by metabolic endocrinology, HIV research, and obesity laboratories
- Competitive research pricing with bulk options
